New hope for Hard-to-Treat cancers: experimental drug targets KRAS mutation

NCT ID NCT07349537

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RMC-5127 (oral tablet)
What this could lead to
If successful, this could lead to a new treatment option for people with hard-to-treat cancers that have a specific KRAS mutation.
What could go wrong
This is an early Phase 1 trial, so the drug may not work or could have serious side effects. It is only for patients who have already tried other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21231, United States

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • NEXT

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT - Dallas

    RECRUITING

    Dallas, Texas, 75039, United States

  • NEXT - Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • START - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

    Contact Email: •••••@•••••

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.